Analysts Offer Predictions for Immunic Q4 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Equities research analysts at Brookline Capital Management issued their Q4 2025 EPS estimates for Immunic in a research note issued on Tuesday, October 15th. Brookline Capital Management analyst T. Bussian anticipates that the company will post earnings of ($0.26) per share for the quarter. The consensus estimate for Immunic’s current full-year earnings is ($0.92) per share.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. During the same quarter in the previous year, the company posted ($0.54) EPS.

Several other research firms have also recently issued reports on IMUX. B. Riley assumed coverage on shares of Immunic in a research report on Tuesday, August 27th. They set a “buy” rating and a $6.00 price objective on the stock. Leerink Partners reiterated an “outperform” rating and set a $5.00 price objective on shares of Immunic in a research report on Monday, September 9th. Piper Sandler reiterated an “overweight” rating and set a $28.00 price objective on shares of Immunic in a research report on Tuesday, July 16th. EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. Finally, Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, September 9th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $11.20.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $1.59 on Thursday. The company has a market capitalization of $143.23 million, a P/E ratio of -0.87 and a beta of 1.84. Immunic has a 1-year low of $0.95 and a 1-year high of $2.11. The firm’s 50 day simple moving average is $1.51 and its two-hundred day simple moving average is $1.35.

Institutional Investors Weigh In On Immunic

Several large investors have recently bought and sold shares of IMUX. Virtu Financial LLC bought a new stake in Immunic in the first quarter worth $25,000. Ikarian Capital LLC increased its position in Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after purchasing an additional 1,162,378 shares during the last quarter. Vanguard Group Inc. increased its position in Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after purchasing an additional 1,703,047 shares during the last quarter. Janus Henderson Group PLC bought a new stake in Immunic in the first quarter worth $9,266,000. Finally, BVF Inc. IL bought a new stake in Immunic in the first quarter worth $11,752,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.